Health Condition 1: C342- Malignant neoplasm of middle lobe,bronchus or lung
Conditions
Interventions
None listed
Sponsors
AstraZeneca Pharma India Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult male or female patients =18 years old or ‘adults’ according to age of majority as defined by the local regulations 2. Patient or next of kin/legal representative is willing and able to provide informed consent according to the local regulations, where applicable 3. Patients with stage IA to IIIB (on the basis of pathologic criteria) NSCLC with adenocarcinoma, or mixed histology with an adenocarcinoma component who have undergone surgical resection of the tumour during the preceding 6 weeksa 4. Availability of FFPE tissue specimen suitable for EGFRm testing (either the primary diagnostic sample or the surgically resected tumour specimen) 5. Availability of medical records at the participating site detailing the initial diagnosis, staging, and surgical management of NSCLC
Exclusion criteria
Exclusion criteria: 1. Histology of the tumour is considered not to be of primary lung in origin 2. Histology is pure squamous cell carcinoma, pure small cell carcinoma, or large cell carcinoma origin lacking any immunohistochemistry evidence of adenocarcinoma differentiation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall proportion of patients with EGFRm • Proportion of EGFRm by the following subgroups: Histology, Pathologic stage, Age, Gender Tobacco smoking, Ethnicity, Family history of lung cancer in first-degree relative, Geographical location.Timepoint: One day | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with the following EGFRm types: Exon19 deletions, Exon21 L858R o Exon20 T790M o Others (compound mutations, uncommon mutations [including G719X, L861Q, S768I, and 20 insertions]) Proportion of patients who were prescribed these modalities: Only surgical resection, Surgical resection and radiotherapy, Surgical resection and systemic therapy (neoadjuvant and/or adjuvant),Surgical resection, radiotherapy and systemic therapy (neoadjuvant and/or adjuvant)Timepoint: One day | — |
Countries
India, Singapore, Taiwan
Contacts
Public ContactAmit Kumar
AstraZeneca Pharma India Ltd
Outcome results
None listed